Craig Millian left Pfizer, where he was the US commercial lead for Lipitor, for Vertex Pharmaceuticals in January 2006. It was a big leap from marketing the industry's biggest drug ever to signing on with an up-and-coming biotech that doesn't yet have a drug on the market, but Millian wanted to be part of building and integrating a commercial model to support the company's "outstanding" pipeline. Millian is proud of the team he's assembled and of the progress they've made in building and integrating commercial capability. Kurt Graves, Vertex EVP, chief commercial officer, and head, strategic development, praises Millian's leadership ability and his drive to innovate. Millian thinks there are misperceptions around motivation in pharma.
Pages to are hidden for
"Millian's mission is patient-centric"Please download to view full document